Rebalix
Vanguard · sheet of 5 September 2026
Vanguard · sheet of 5 September 2026ETF sheet · official issuer and register data
Vanguard FTSE North America UCITS ETF (USD) Accumulating
VNRA · IE00BK5BQW10 · USD · domicile Ireland
Equity · North AmericaSFDR art. 6 (inferred)
Index tracked: FTSE North America Index
- TER
- 0.08%+ trans. 0.03%
- Fund size
- 5.7 bn EUR
- Tracking difference
- +0.17%3-year avg
- 🇮🇹 tax rate
- 26.00%equity
- Replication
- Physical
- Income
- Accumulating
Launch 23 Jul 2019 · costs from the KID as of 2 Sept 2026 · 604 securities held · 9 venues (ESMA register)
The fund’s objective — in the issuer’s words
From the Key Information Document (KID) · 4 Aug 2026
The Fund employs a passive management – or indexing – investment approach, through physical acquisition of securities, and seeks to track the performance of the FTSE North America Index (the “Index”). The Index is comprised of large and mid-sized company stocks in North America. The Fund attempts to: 1. The Fund attempts to track the performance of the Index by investing all, or substantially all, of its assets in the stocks that make up the Index in approximately the same proportion as the Index. 2. Remain fully invested except in extraordinary market,…
Performance since series start (in euro) — base 100
31 Aug 2019 → 31 Jul 2026 · dividends reinvested where declared by the issuer · converted at ECB rates
Returns in euro
| 1 year | +24.2% |
| 3 years | +62.4% |
| 5 years | +87.3% |
| 10 years | series too young |
| Since series start | +165.6% |
Risk · 1 / 3 / 5 years
| Volatility (ann.) | 12.56% | 14.73% | 16.80% |
| Max drawdown | −8.94% | −18.70% | −25.24% |
| Sharpe | 1.39 | 1.14 | 0.61 |
| Sortino | 2.02 | 1.67 | 0.87 |
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · VNRA · IE00BK5BQW101
RebalixVNRA · IE00BK5BQW10 · sheet of 5 September 2026
Tracking difference — year by year
Fund minus index, complete calendar years · from issuer-declared series
| Year | Fund | Index | TD |
|---|---|---|---|
| 2025 | +18.28% | +18.16% | +0.12% |
| 2024 | +24.27% | +24.11% | +0.16% |
| 2023 | +26.19% | +25.96% | +0.23% |
| 2022 | −19.26% | −19.39% | +0.13% |
| 2021 | +26.58% | +26.42% | +0.16% |
Holdings
Portfolio as declared by the issuer · 31 Jul 2026 · 604 securities · top-10 weight = 35.0%
| Top holdings | Weight |
|---|---|
| 6.9% | |
| 6.5% | |
| 5.1% | |
| 3.9% | |
| 3.0% | |
| 2.7% | |
| 2.5% | |
| 1.8% | |
| 1.4% | |
| 1.4% |
Countries (% of fund)
Sectors (% of fund)
Listing venues
ESMA register (FIRDS) and official exchange lists
VNRA · Borsa Italiana (ETFplus), Börse Düsseldorf, Börse Frankfurt, Börse Hamburg, Börse Hannover, Börse München / gettex, Börse Stuttgart, Tradegate Exchange, Xetra (Deutsche Börse)
+ 19 unmapped venues (MTF, RFQ, professional)
Official documents
Clickable links in the PDF
Prospectus · fund-docs.vanguard.com/etf-prospectus-en.pdf
The live sheet, always up to date
rebalix.com/en/etf/IE00BK5BQW10
Series, distributions, holdings and documents refresh daily.
rebalix.com/en/etf/IE00BK5BQW10
Series, distributions, holdings and documents refresh daily.
Sheet produced on 5 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV and total-return series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.
Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.
Rebalix · VNRA · IE00BK5BQW102